

Interview Summary	Application No. 10/003,136	Applicant(s) WONG-MADDEN ET AL.	
	Examiner Christian L. Fronda	Art Unit 1652	

All participants (applicant, applicant's representative, PTO personnel):

- (1) Christian L. Fronda. *CLF* (3) Harriet M. Strimpel.
 (2) Ponnathapura Achutamurthy. (4) _____.

Date of Interview: 10 January 2006.

Type: a) ☒ Telephonic b) ☐ Video Conference
 c) ☐ Personal [copy given to: 1) ☐ applicant 2) ☐ applicant's representative]

Exhibit shown or demonstration conducted: d) ☐ Yes e) ☒ No.
 If Yes, brief description: _____.

Claim(s) discussed: 7,10,11 and 14-18.


Identification of prior art discussed: Ichikawa et al., Frank et al., Su et al..

Agreement with respect to the claims f) ☐ was reached. g) ☒ was not reached. h) ☐ N/A.


Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: See Continuation Sheet.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN A NON-EXTENDABLE PERIOD OF THE LONGER OF ONE MONTH OR THIRTY DAYS FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.


 PONNATHAPUACHUTAMURTHY
 SUPERVISORY PATENT EXAMINER
 TECHNOLOGY CENTER 1600

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.


 Examiner's signature, if required

Continuation of Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: The rejections of the claims under 35 USC 112, 1st paragraph, and 35 USC 103 were discussed. Applicants traversed the written description rejection by arguing that the recited glycosidase from the *Xanthomonas* species were adequately described in the specification and that the said glycosidase were previously allowed in related cases US Serial Nos. 08/560,809 and 08/596,250. Applicants traverse the rejection of the claims under 35 USC 103 by arguing that the references do not specifically teach a purified glycosidase from *Xanthomonas holcicola*, *Xanthomonas manihotis*, or *Xanthomonas oryzae*, where said glycosidase has a specific and defined substrate specificity.